pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

BOEHRINGER INGELHEIM

USupdated 3mo ago
Website ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Unknown: 1
1Unknown
drug
JENTADUETO XR

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatmentnot yet recruitingn=70
  • phase1A Study to Test How Well Different Doses of BI 3821001 Are Tolerated by Healthy Peoplerecruitingn=40
  • phase3ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Diseasenot yet recruitingn=600
  • phase1A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the Bloodactive not recruitingn=10
  • phase2PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Diseaserecruitingn=132
  • phase3A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failurerecruitingn=6,712
  • phase3A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamignot yet recruitingn=68
  • phase1A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heartactive not recruitingn=56
🐶 Hiring Signal
617 open roles at BOEHRINGER INGELHEIM →

Where BOEHRINGER INGELHEIM is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 33Cardiovascular 24Immunology & Inflammation 13Metabolic 11Respiratory 2CNS / Neuroscience 2
departmentBusiness Development & Sales 71IT & Engineering 60R&D / Discovery 40Commercial 37People & Talent 20Quality 18

News

  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…
    biospace · 1d ago
  • Their loss, our gain? Canada makes its case to Europe amid U.S. instability
    Companies at BIO-Europe said shifting U.S. politics have created an opening to promote Canada’s strengths to European partners.
    biospace · 2d ago
  • Gubra CEO gets the quick hook; Ex-HHS official Brett Giroir takes over at cancer biotech
    → AbbVie and Boehringer Ingelheim’s Danish obesity partner Gubra is going with a co-CEO arrangement after the abrupt departure of Markus Rohrwild. Endpoints News just spoke with Rohrwild last month…
    endpoints · 6d ago
  • Drug price hikes in Germany could push US costs higher, study says
    The report comes amid escalating tensions between the U.S. and Germany over drug prices, with several large pharmaceutical companies responding by scaling back investments in the country.
    biopharma_dive · 7d ago
  • Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
    Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…
    biospace · 8d ago
  • Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder
    Having linked its glucagon/GLP-1 candidate to a significant reduction in heavy drinking days, Altimmune is preparing to speak to the FDA in December about the design of a Phase 3 program.
    biospace · 9d ago
  • FDA orders class-wide GLP-1 label update to include potential risk for rare eye disease
    Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
    biospace · 9d ago
  • Boehringer, Zealand’s obesity drug doesn’t elevate heart risk in key late-stage test
    The Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk f…
    biospace · 9d ago
  • #AHA26: Boehringer to seek approval of obesity shot, but gaining market share could be tricky
    Boehringer Ingelheim will seek approval for its incretin shot survodutide for obesity next year, after a trial showed that the drug doesn’t increase patients’ risk of cardiovascular events like hea…
    endpoints · 9d ago
  • Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down
    The deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.
    biopharma_dive · 13d ago
view all news mentions →
identifiers
country
US
source
openfda_drugsfda
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?